Table 2.
Paired groups | Toxo positivity (No./%) | IgG level (IU/ml) (Avg. ± SD) |
P-value* |
---|---|---|---|
Schizophrenia (14–25 years) (n = 8) and Control (n = 55) |
1 (12.5) 8 (14.55) |
28 ± 14.64 9.98 ± 1.78 |
0.063 |
MDD (14–25 years) (n = 10) and Control (n = 55) |
0 (0.00) 8 (14.55) |
7.81 ± 5.85 9.98 ± 1.78 |
0.156 |
Schizophrenia (14–25 years) (n = 8) and MDD (14–25 years) (n = 10) |
20 (31.57) 0 (0.00) |
28 ± 14.64 7.81 ± 5.85 |
0.059 |
Schizophrenia (26–35 years) (n = 25) and Control (n = 55) |
6 (24) 8 (14.55) |
76.36 ± 14.73 9.98 ± 1.78 |
0.001 |
MDD (26–35 years) (n = 19) and Control (n = 55) |
6 (31.58) 8 (14.55) |
73.8 ± 19.62 9.98 ± 1.78 |
0.001 |
Schizophrenia (26–35 years) (n = 25) and MDD (26–35 years) (n = 19) |
6 (24) 6 (31.58) |
76.36 ± 14.73 73.8 ± 19.62 |
0.416 |
Schizophrenia (36–50 years) (n = 30) and Control (n = 55) |
13 (43.33) 8 (14.55) |
71.73 ± 18.31 9.98 ± 1.78 |
0.001 |
MDD (36–50 years) (n = 10) and Control (n = 55) |
4 (40) 8 (14.55) |
86.17 ± 26.84 9.98 ± 1.78 |
0.002 |
Schizophrenia (36–50 years) (n = 30) and MDD (36–50 years) (n = 10) |
13 (43.33) 4 (40) |
71.73± 18.31 86.17 ± 26.84 |
0.352 |
*Significant difference if P < 0.05.